BioNTech SE
NASDAQ · us_market
No AI summary generated yet for this ticker.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
European equities traded in the US as American depositary receipts were rising late Friday morning,
European equities traded in the US as American depositary receipts were trending slightly lower late
BioNTech's (BNTX) cancer-drug pipeline is showing stronger early results and is approaching several
European equities traded in the US as American depositary receipts were tracking lower late Wednesda
BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Dai moved off the sidelines Wednesday as he upgraded BioNTech stock to Buy from Neutral with a $135 price target, up from $117.
UBS analyst David Dai upgrades BioNTech (NASDAQ:BNTX) from Neutral to Buy and raises the price target from $117 to $135.
Bristol-Myers Squibb Company targets upper-end 2026 guidance on Breyanzi, Camzyos & Reblozyl growth; ASCO 2026 catalysts ahead. Click for this BMY update.
Bernstein analyst Jeffrey Walch initiates coverage on BioNTech (NASDAQ:BNTX) with a Market Perform rating and announces Price Target of $96.
BioNTech (NasdaqGS:BNTX) has drawn fresh attention after shareholders approved expanding its Supervisory Board at the 2026 AGM, adding Prof. Iris Löw Friedrich and Dr. Susanne Schaffert to deepen clinical and oncology expertise. See our latest analysis for BioNTech. BioNTech’s share price has been under pressure despite the latest board expansion, with the stock down 14.10% on a 1 month share price return basis and showing a 1 year total shareholder return decline of 8.81%. This suggests...
BioNTech (NasdaqGS:BNTX) has drawn fresh attention after shareholders approved expanding its Supervisory Board at the 2026 AGM, adding Prof. Iris Löw Friedrich and Dr. Susanne Schaffert to deepen clinical and oncology expertise. See our latest analysis for BioNTech. BioNTech’s share price has been under pressure despite the latest board expansion, with the stock down 14.10% on a 1 month share price return basis and showing a 1 year total shareholder return decline of 8.81%. This suggests...
Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commercial franchises.
Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commercial franchises.
BioNTech’s 2026 AGM approved an expansion of the Supervisory Board. Two new members with backgrounds in oncology, commercialization, and clinical development were appointed. The board change aligns with areas closely linked to BioNTech’s current pipeline and product ambitions. For investors watching NasdaqGS:BNTX, this governance update arrives after a period of weaker share performance. The stock closed at $87.79, with the share price down 6.3% over the past week, 14.7% over the past...
BioNTech’s 2026 AGM approved an expansion of the Supervisory Board. Two new members with backgrounds in oncology, commercialization, and clinical development were appointed. The board change aligns with areas closely linked to BioNTech’s current pipeline and product ambitions. For investors watching NasdaqGS:BNTX, this governance update arrives after a period of weaker share performance. The stock closed at $87.79, with the share price down 6.3% over the past week, 14.7% over the past...
European equities traded in the US as American depositary receipts were heading higher late Monday m
European equities traded in the US as American depositary receipts were heading higher late Monday m
MAINZ, Germany - BioNTech SE held its Annual General Meeting today. A total of 92 per cent of the share capital was represented at the virtual assembly. All resolutions proposed on the agenda items...
BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2
BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 5.71M | $507.44M | 0.03% | Trimmed-3.8% | 2026-03-31 |
| DEShaw | quant | 199.8K | $17.76M | 0.01% | Trimmed-59.1% | 2026-03-31 |
| StateStreet | passive | 180.6K | $16.05M | 0.00% | Added+20.1% | 2026-03-31 |
| TwoSigma | quant | 166.2K | $14.77M | 0.01% | Added+53.5% | 2026-03-31 |
| Wellington | fundamental | 135.0K | $12.00M | 0.00% | Added+933.3% | 2026-03-31 |
| ARKK | disruptive | 127.9K | $11.37M | 0.09% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | -2.33 | — | — |
| 2026-05-05 | -1.92 | -1.95 | -1.62% |
| 2026-03-10 | -0.25 | -0.33 | -30.43% |
| 2025-11-03 | 0.10 | -0.12 | -220.34% |
| 2025-08-04 | -1.41 | -1.60 | -13.84% |
| 2025-05-05 | -2.35 | -1.73 | +26.29% |
| 2025-03-10 | 0.37 | 1.08 | +188.88% |
| 2024-11-04 | -1.61 | 0.81 | +150.43% |
| 2024-08-05 | -2.04 | -3.36 | -64.44% |
| 2024-05-06 | -1.35 | -1.31 | +2.86% |
| 2024-03-20 | 2.45 | 1.90 | -22.45% |
| 2023-11-06 | -0.67 | 0.67 | +200.47% |
| 2023-08-07 | -0.73 | -0.79 | -8.64% |
| 2023-05-08 | 0.52 | 2.05 | +294.18% |
| 2023-03-27 | 7.77 | 9.26 | +19.21% |
| 2022-11-07 | 3.42 | 6.98 | +104.33% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BNTX | -1.63% | -4.77% | +0.79% | +0.15% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -4.60% | -0.14% | +4.23% | -12.54% |